ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,580 Cr (+22.8% YoY) and net profit of ₹292.5 Cr (+36.2% YoY) for Q1 FY27.
Emcure Pharmaceuticals reported strong FY26 results with consolidated revenue growing 16.6% YoY to ₹9,203.54 Crore, crossing the $1 billion milestone. Reported PAT rose 33.1% to ₹941 Crore. International markets drove growth, up 22.2%, while domestic sales grew 10%. The Board recommended a final dividend of ₹3.60 per share.
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,470 Cr (+16.7% YoY) and net profit of ₹243.7 Cr (+23.6% YoY) for Q4 FY26.
Emcure Pharmaceuticals approved its FY26 audited results, reporting consolidated revenue of ₹9,204 Crore and PAT of ₹941 Crore. The board recommended a final dividend of ₹3.60 per share. Key leadership re-appointments include Mr. Satish Mehta as Managing Director for five years and Dr. Mukund Gurjar as Whole-time Director for one year.